Imperial College London
Alternate

DrSanjayPopat

Faculty of Medicine, National Heart & Lung Institute

Reader in Cancer Medicine
 
 
 
//

Contact

 

+44 (0)20 7808 2132s.popat Website

 
 
//

Location

 

Royal Marsden HospitalThe Royal Marsden Hospital

//

Summary

 

Publications

Citation

BibTex format

@article{Joshi:2021:10.1016/j.lungcan.2021.04.021,
author = {Joshi, K and Muhith, A and Obeid, M and Milner-Watts, C and Yousaf, N and Popat, S and Davidson, M and Bhosle, J and O'Brien, M and Minchom, A},
doi = {10.1016/j.lungcan.2021.04.021},
journal = {Lung Cancer},
pages = {147--150},
title = {Safety monitoring of two and four-weekly adjuvant durvalumab for patients with stage III NSCLC: implications for the COVID-19 pandemic and beyond},
url = {http://dx.doi.org/10.1016/j.lungcan.2021.04.021},
volume = {156},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Durvalumab is the first approved adjuvant immunotherapy agent for patients with stage III NSCLC treated with concurrent chemoradiotherapy and is associated with improved overall survival. In order to minimise the number of hospital visits for patients receiving durvalumab during the COVID-19 pandemic we implemented 4-weekly (20 mg/kg) durvalumab in place of 2-weekly infusions at The Royal Marsden Hospital. We assessed the potential impact of the safety of a 4-weekly schedule in patients receiving adjuvant durvalumab. We carried out a retrospective study of 40 patients treated with 2-weekly and 4-weekly infusions of durvalumab prior to and during the COVID-19 pandemic. Clinical documentation was analysed from 216 consultations across 40 patients receiving 2-weekly durvalumab and 66 consultations of 14 patients who switched from 2-weekly to 4-weekly durvalumab during the COVID-19 pandemic. In patients receiving 2-weekly durvalumab, the rate of grade 3 and 4 toxicities was 15 % compared to 7% in patients receiving 4-weekly durvalumab. Pre-existing autoimmune disease was considered a risk factor for the development of grade 3 or 4 toxicities. We did not observe any difference in the rate of grade 1 and 2 toxicities between the two groups. Our findings support the use of 4-weekly durvalumab during the COVID-19 pandemic and beyond, obviating the need for 2-weekly face-to-face consultations and blood tests, relevant given the current pandemic and the need to re-structure cancer services to minimise patient hospital visits and exposure to SARS-CoV-2.
AU  - Joshi,K
AU  - Muhith,A
AU  - Obeid,M
AU  - Milner-Watts,C
AU  - Yousaf,N
AU  - Popat,S
AU  - Davidson,M
AU  - Bhosle,J
AU  - O'Brien,M
AU  - Minchom,A
DO  - 10.1016/j.lungcan.2021.04.021
EP  - 150
PY  - 2021///
SN  - 0169-5002
SP  - 147
TI  - Safety monitoring of two and four-weekly adjuvant durvalumab for patients with stage III NSCLC: implications for the COVID-19 pandemic and beyond
T2  - Lung Cancer
UR  - http://dx.doi.org/10.1016/j.lungcan.2021.04.021
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000652674900021&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - https://www.sciencedirect.com/science/article/pii/S016950022100163X?via%3Dihub
VL  - 156
ER  -
Download